---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-090423"
form_type: "8-K"
ticker: "LIMN"
cik: "0001971387"
company_name: "Liminatus Pharma, Inc."
filed_at: "2026-08-04T20:30:44+00:00"
generated_at: "2026-08-04T20:33:31.135122+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Liminatus Pharma shareholders approve reverse stock split authorization up to 1-for-50 at annual meeting

## Summary
- Elected Class I directors Nicholas Fernandez and Dr. Ji Yeon Baek with ~23.4M votes for each; broker non-votes 8.8M.
- Ratified WithumSmith+Brown as independent auditor for FY2026; 31.5M for, 0.89M against, 63k abstain.
- Approved reverse stock split authorization up to 1-for-50 at Board's discretion to meet Nasdaq minimum bid price; 30.1M for, 2.3M against.
- Quorum of 48.31% (32.4M shares) represented at the August 3, 2026 annual meeting.

## SEC filing metadata
- accession: 0001104659-26-090423
- form_type: 8-K
- ticker: LIMN
- cik: 0001971387
- company_name: Liminatus Pharma, Inc.
- filed_at: 2026-08-04T20:30:44+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971387/000110465926090423/0001104659-26-090423-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971387/000110465926090423/tm2622207d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-090423
- JSON: https://secwatch.observer/filing/0001104659-26-090423.json
- Plain text: https://secwatch.observer/filing/0001104659-26-090423.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.